dilazep has been researched along with tetradecanoylphorbol acetate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, CW | 1 |
| Deguchi, H; Gabazza, EC; Hayashi, N; Suzuki, K; Takeya, H; Urano, H; Wada, H | 1 |
2 other study(ies) available for dilazep and tetradecanoylphorbol acetate
| Article | Year |
|---|---|
Decrease in equilibrative uridine transport during monocytic differentiation of HL-60 leukaemia: involvement of protein kinase C.
Topics: Affinity Labels; Alkaloids; Binding Sites; Biological Transport; Cell Differentiation; Dilazep; Dipyridamole; Humans; Kinetics; Leukemia; Monocytes; Protein Kinase C; Staurosporine; Tetradecanoylphorbol Acetate; Thioinosine; Thymidine; Tumor Cells, Cultured; Uracil; Uridine | 1994 |
Dilazep, an antiplatelet agent, inhibits tissue factor expression in endothelial cells and monocytes.
Topics: Adenosine; Dilazep; Endothelium, Vascular; Gene Expression; Humans; Monocytes; Platelet Aggregation Inhibitors; Purinergic P1 Receptor Agonists; Tetradecanoylphorbol Acetate; Theophylline; Thrombin; Thromboplastin; Tumor Necrosis Factor-alpha | 1997 |